Condition
Cytokine Release Syndrome clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Cytokine Release Syndrome clinical trials that are recruiting, at sites in 2 countries (most in United States (4), China (1)). By phase: Phase 1 (2), Phase 2 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 2Countries
Newest Cytokine Release Syndrome clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Infliximab to Help Prevent CRS During Teclistamab or Talquetamab Therapy in Relapsed/Refractory Myeloma | Phase 2 | Columbus, Ohio | Recruiting | Jun 18, 2026 |
| Remote rehabilitation for people receiving CAR-T cell therapy | — | Salt Lake City, Utah | Recruiting | Feb 5, 2026 |
| Methylene blue added to treat CAR‑T–related CRS and ICANS | Phase 1 | Tianjin, Tianjin Municipality | Recruiting | Sep 11, 2025 |
| Preventing cytokine release syndrome with siltuximab before epcoritamab treatment | Phase 1 | Cleveland, Ohio | Recruiting | Jun 7, 2024 |
| Using CTO1681 to prevent cytokine release syndrome in DLBCL patients receiving CAR T-cell therapy | Phase 1/2 | Orange, California and 5 other locations | Recruiting | Jun 15, 2023 |
All recruiting trials (5)
-
Infliximab to Help Prevent CRS During Teclistamab or Talquetamab Therapy in Relapsed/Refractory Myeloma
This phase 2 trial tests whether infliximab can prevent cytokine release syndrome in patients with relapsed or refractory multiple myeloma who are being treated with teclistamab or talquetamab.
-
Remote rehabilitation for people receiving CAR-T cell therapy
This project will test a home-based telerehabilitation program using interactive exercise, nutrition, behavioral support, and remote monitoring for people with lymphoma or myeloma who are getting CAR-T therapy.
-
Methylene blue added to treat CAR‑T–related CRS and ICANS
This study will test whether giving methylene blue alongside standard care helps people who develop CRS or ICANS after CAR‑T cell or bispecific antibody therapy.
-
Preventing cytokine release syndrome with siltuximab before epcoritamab treatment
This study is testing if giving siltuximab before treatment with epcoritamab can help prevent serious side effects in people with large B-cell lymphoma or follicular lymphoma.
-
Using CTO1681 to prevent cytokine release syndrome in DLBCL patients receiving CAR T-cell therapy
This study is testing if a new drug called CTO1681 can help prevent serious side effects in adults with diffuse large B-cell lymphoma who are getting CAR T-cell therapy.
Related topics
Quick answers
How many Cytokine Release Syndrome clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (4 trials), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2, Phase 2: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.